ChemWerth Inc.
David Moore has extensive experience in leadership and strategic roles across various industries. Currently serving as Chief Strategy Officer and a member of the Board of Directors at ChemWerth since June 2004, David also owns the General Stanton Inn and holds positions as President of WerthMoore Consulting and Chairman of Silly Cow Farms LLC. Previously, David has held senior roles, including President at 126Boon and Senior Vice President at QBE North America. Additional experience includes Vice President roles at The Hanover Insurance Group and The Hartford, as well as Vice President of Marketing at Konica Minolta Business Solutions U.S.A., Inc. David holds a Bachelor's degree in Political Science from the University of Rhode Island and an MBA in Management from the University of Hartford, with further education at Columbia Business School and Johnson & Wales University.
This person is not in any teams
This person is not in any offices
ChemWerth Inc.
1 followers
LEADING THE SUPPLY OF HIGH QUALITY GENERIC APIs 21st Century economic, social, technical and regulatory dynamics are dramatically changing the pharmaceutical world making it more challenging than ever to find profitable opportunities. That's why it's important to work with a supply-partner who knows how to navigate through the tough issues, help you overcome obstacles and get you to the market fast to gain competitive advantage. Established in 1982, ChemWerth is a full service generic drug development and supply company providing high quality API's to regulated markets worldwide. Through exclusive development and partnerships with API manufacturers, ChemWerth provides expertise in product selection and development, analytical and regulatory services, and strong project management to ensure the highest standards of quality. We are committed to providing our customers with a distinct competitive advantage. Our team of technical, analytical, regulatory and marketing experts can enhance your business by: 1. Advancing your product development; 2. Ensuring the manufacturing facilities we represent maintain a high level of compliance with ever-evolving cGMPs; 3. Collaborating with manufacturers in establishing appropriate protocols and methodologies to prepare a sound and complete DMF; 4. Sourcing APIs from China, India, Germany and the US to provide our customers with the best value; and 5. Advancing Paragraph IV filings through our exclusive API development and supply partnerships.